Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Mar 5, 2013

Top 20 Best-Selling Drugs of 2012

Which drugs were the biggest hits last year?

Top 20 Best-Selling Drugs of 2012

These medications topped the list of money-makers last year. [© grandeduc - Fotolia.com]

  • #10. Cymbalta (duloxetine)

    Drug maker: Eli Lilly

    Indication(s): Major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and fibromyalgia; management of chronic musculoskeletal pain due to chronic osteoarthritis pain and chronic low back pain

    2012 sales: $4.994 billion

    2011 sales: $4.161 billion

    % change: 20.0%

    Q4 2012 sales: $1.420 billion, up 20.3% from $1.181 billion in Q4 2011

  • #9. Avastin (bevacizumab)

    Drug maker: Roche

    Indication(s): Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney

    2012 sales: $6.260 billion (CHF 5.764 billion)3

    2011 sales: $5.747 billion (CHF 5.292 billion)3

    % Change: 6% at CER

    Q4 2012 sales: $1.580 billion (CHF 1.455 billion), up 7.8% from $1.466 billion (CHF 1.350 billion) in Q4 20113

  • #8. Crestor (rosuvastatin calcium)

    Drug maker: AstraZeneca

    Indication(s): Reduction of Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides in the blood, as an adjunct to diet

    2012 sales: $6.253 billion

    2011 sales: $6.622 billion

    % Change: -4% at CER

    Q4 2012 sales: $1.622 billion, down 7% at CER from $1.771 billion in Q4 2011

  • #7. Herceptin (trastuzumab)

    Drug maker: Roche

    Indication(s): HER2-positive breast cancer and HER2-positive metastatic gastric cancer

    2012 sales: $6.397 billion (CHF 5.889 billion)4

    2011 sales: $5.706 billion (CHF 5.253 billion)4

    % Change: 11% at CER

    Q4 2012 sales: $1.583 billion (CHF 1.457 billion), up 8.1% from $1.464 billion (CHF 1.348 billion) in Q4 20114

  • #6. Lantus (insulin glargine)

    Drug maker: Sanofi

    Indication(s): Once daily treatment for diabetes

    2012 sales: $6.648 billion (€4.960 billion)5

    2011 sales: $5.249 billion (€3.916 billion)5

    % Change: 19.3% at CER

    Q4 2012 sales: $1.789 billion (€1.335 billion), up 22.6% at CER from $1.413 billion (€1.054 billion) in 4Q 2011 at CER5

  • #5. Rituxan (rituximab, MabThera)

    Drug maker: Roche

    Indication(s): Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis

    2012 sales: $7.285 billion (CHF 6.707 billion)6

    2011 sales: $6.523 billion (CHF 6.005 billion)6

    % Change: 9% at CER

    Q4 2012 sales: $1.856 billion (CHF 1.709 billion), up 7.6% from $1.725 billion (CHF 1.588 billion) in Q4 20116

  • #4. Advair (fluticasone and salmeterol; sold in some countries as Seretide)

    Drug maker: GlaxoSmithKline

    Indication(s): Asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

    2012 sales: $7.904 billion (£5.046 billion)7

    2011 sales: $7.928 billion (£5.061 billion)7

    % Change: 1% at CER

    Q4 2012 sales: $2.051 billion (£1.309 billion), down 1% at CER from $2.050 billion (£1.351 billion)7

  • #3. Enbrel (etanercept)

    Drug maker: Amgen and Pfizer8

    Indication(s): Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis

    2012 sales: $7.963 billion [$4.236 billion Amgen + $3.737 billion Pfizer]

    2011 sales: $7.367 billion [$3.701 billion Amgen + $3.666 billion Pfizer]

    % Change: 8%

    Q4 2012 sales: $2.118 billion, up 13% from $1.870 billion in Q4 2011
    [2012: $1.161 billion Amgen + 0.957 billion Pfizer]
    [2011: $0.945 billion Amgen + 0.925 billion Pfizer]

  • #2. Remicade (infliximab)

    Drug maker: Johnson & Johnson and Merck & Co.

    Indication(s): Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn's Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines

    2012 sales: $8.215 billion [$6.139 billion J&J + $2.076 billion Merck & Co.]

    2011 sales: $8.159 billion [$5.492 billion J&J + $2.667 billion Merck & Co.]

    % Change: 0.7%

    Q4 2012 sales: $2.053 billion, up 5.9% from $1.939 billion in Q4 2011
    [2012: $1.504 billion J&J + $0.549 billion Merck & Co.]
    [2011: $1.428 billion J&J + $0.511 billion Merck & Co.]

  • #1. Humira (adalimumab)

    Drug maker: AbbVie9

    Indication(s): Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis

    2012 sales: $9.265 billion

    2011 sales: $7.932 billion

    % Change: 19.3%

    Q4 2012 sales: $2.681 billion, up 31.1% from $2.178 billion in Q4 2011



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »